List of Excipients in Branded Drug MICONAZOLE 7

« Back to Dashboard

Generic Drugs Containing MICONAZOLE 7

Company	Ingredient	NDC	Excipient
Walgreens	miconazole nitrate	0363-0730	APRICOT KERNEL OIL PEG-6 ESTERS
Walgreens	miconazole nitrate	0363-0730	BENZOIC ACID
Walgreens	miconazole nitrate	0363-0730	BUTYLATED HYDROXYANISOLE

What are the Most Frequently-Used Excipients in MICONAZOLE 7?

# Of NDCs	Excipient
23	APRICOT KERNEL OIL PEG-6 ESTERS
32	BENZOIC ACID
29	BUTYLATED HYDROXYANISOLE

Miconazole 7 Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 6, 2026

Miconazole 7 is a seven-day vaginal antifungal regimen containing miconazole nitrate, generally supplied as a 2% vaginal cream or 100 mg vaginal suppository. Its commercial opportunity is driven by OTC monograph compliance, formulation performance, applicator design, retailer access, and brand positioning rather than active-ingredient patent exclusivity. The core miconazole molecule is long off patent, and generic entry does not depend on a traditional Paragraph IV challenge.

What is Miconazole 7 and how is it regulated?

Miconazole 7 is a dosage regimen, not a single globally standardized product. Products sold under this description commonly use one of two dosage forms:

Product format	Typical strength	Administration	Typical treatment period
Vaginal cream	Miconazole nitrate 2%	One prefilled applicator nightly	Seven days
Vaginal suppository or ovule	100 mg miconazole nitrate	One vaginal unit nightly	Seven days

In the United States, miconazole nitrate vaginal products may be marketed under the FDA’s OTC antifungal monograph when they meet the applicable active-ingredient, dosage-form, labeling, and testing requirements. The relevant framework is FDA’s OTC Monograph M013 and 21 C.F.R. Part 333, Subpart D.[1,2]

The standard consumer population is adults and children aged 12 years and older. Labeling generally directs users to seek medical advice for first-time symptoms, recurrent infections, pregnancy-related concerns, fever, abdominal pain, foul-smelling discharge, or lack of improvement.

What excipients are used in Miconazole 7 formulations?

Excipient selection differs materially between vaginal creams and solid vaginal dosage forms. Commercial products should be evaluated against five performance criteria: drug uniformity, vaginal retention, leakage control, irritation potential, and compatibility with packaging and barrier contraceptives.

What excipients are used in miconazole 7 vaginal cream?

A representative miconazole nitrate 2% vaginal cream uses a water-containing emulsion or emulsion-like base. Publicly available labeling for branded miconazole vaginal cream products identifies excipients such as mineral oil, purified water, stearyl alcohol, white petrolatum, and benzoic acid.[3]

The functional roles are:

Excipient class	Commercial function	Key development issue
Mineral oil	Emolliency, drug dispersion, lubrication	May weaken latex condoms and diaphragms
White petrolatum	Occlusivity, vaginal retention, emolliency	Can increase residue and leakage
Stearyl alcohol	Consistency, emulsion stabilization, texture	Can affect spreadability and sensory acceptance
Purified water	Continuous phase and processing medium	Requires microbial control
Benzoic acid	Preservative or pH-control contribution	Irritation and preservative-efficacy balance

The cream base should maintain miconazole nitrate as a stable, uniformly distributed suspension or dispersed phase. Because miconazole nitrate has limited water solubility, the formulation may depend on particle-size control, wetting, oil-phase selection, and high-shear mixing.

What excipients are used in miconazole 7 suppositories?

Suppository or ovule products generally use a lipophilic or self-emulsifying base. Candidate excipient systems include hydrogenated vegetable oils, hard fats, fatty-acid esters, glycerides, and polyethylene glycol systems.

A solid vaginal dosage form requires control of:

• Melting or softening behavior at vaginal temperature.
• Mechanical strength during packaging and insertion.
• Drug distribution throughout the unit.
• Release from the base into vaginal fluid.
• Residue, leakage, and patient comfort.
• Stability under elevated temperature conditions.

Lipophilic bases can improve residence and patient familiarity but may create greater leakage and latex-barrier concerns. Polyethylene glycol systems can provide higher physical stability and lower oil content, but they may cause osmotic discomfort or increase local irritation if the molecular-weight profile is poorly selected.

What excipient strategies create commercial differentiation?

The strongest opportunities are incremental formulation improvements rather than new miconazole chemistry.

Low-irritation and sensitive-use formulations

A sensitive-use product could reduce unnecessary fragrance, colorants, and high-irritancy surfactants. A lower-preservative or preservative-free presentation may have consumer appeal, but the manufacturer must address microbial quality, package integrity, and in-use contamination.

Potential positioning includes:

• Fragrance-free formulation.
• Low-residue cream.
• Reduced-leakage ovule.
• Dermatologically tested external comfort cream packaged separately.
• Product designed for users reporting irritation from existing bases.

Claims must remain consistent with the OTC monograph and supported by appropriate testing. A formulation cannot imply superior cure rates without clinical evidence.

Reduced leakage and improved retention

Leakage is a practical limitation of seven-day vaginal therapy. Commercial development can focus on:

• Higher-yield-value cream rheology.
• Mucoadhesive polymers.
• Controlled softening of ovules.
• Applicators that deposit the dose farther into the vaginal canal.
• Packaging that reduces premature melting or deformation.

Mucoadhesive excipients may include selected cellulose derivatives, carbomers, polycarbophil-type polymers, or other vaginally compatible polymers. Their use requires testing for drug release, local tolerability, applicator force, and interference with latex contraceptives.

Barrier-contraceptive compatibility

Oil-containing miconazole vaginal products may damage latex condoms and diaphragms during treatment and for a period after use specified in product labeling. This limitation creates a clear development opportunity for an aqueous, non-oil, or latex-compatible formulation.

A reformulated product could support differentiated labeling if testing demonstrates compatibility with relevant condom and diaphragm materials. Testing should include tensile strength, burst pressure, elongation, and failure analysis after exposure to the finished product.

Applicator and packaging differentiation

The applicator is part of the commercial product, not a secondary component. Opportunities include:

• Individually wrapped, prefilled applicators.
• Lower-force applicator systems.
• Applicators with improved dose retention.
• Tamper-evident packaging.
• Unit-dose packaging optimized for heat exposure.
• Retail packs containing external symptom-relief products.

Applicator improvements may support device or combination-product patent claims even where the drug composition is unprotected.

What patents protect Miconazole 7 products?

The active ingredient has no meaningful remaining composition-of-matter exclusivity in the U.S. Miconazole was introduced decades ago, and the basic compound is available from multiple manufacturers. The commercial patent landscape is therefore likely to center on secondary rights.

Potential patent categories include:

Patent category	Relevance to Miconazole 7	Entry risk
Active ingredient	Basic miconazole chemistry	Low; historical patents expired
Vaginal composition	Base, polymer, particle size, release profile	Product-specific
Manufacturing process	Mixing, granulation, filling, cooling, sterilization	Moderate if narrowly claimed
Applicator	Dose delivery, insertion, leakage reduction	Moderate
Packaging	Heat protection, unit-dose systems, barrier packaging	Usually limited
Method of use	Treatment of vulvovaginal candidiasis or symptom control	Low for routine monograph use
Combination product	Miconazole plus external antipruritic or adjunctive agent	Product-specific

No single patent estate governs all products marketed as Miconazole 7. Patent strength depends on claim scope, prosecution history, continuation activity, ownership, and whether the claims cover the commercial formulation rather than a research prototype.

What is the Orange Book status of Miconazole 7?

Miconazole 7 OTC monograph products generally do not rely on an NDA-based Orange Book listing. They are regulated through the OTC monograph framework rather than through the standard reference-listed-drug and ANDA pathway used for many prescription products.[1,4]

The practical consequences are:

• No conventional Orange Book patent-listing strategy for a compliant monograph product.
• No routine Paragraph IV certification against an Orange Book-listed patent.
• No Hatch-Waxman 30-month stay arising solely from entry into the monograph market.
• Competitive entry based on regulatory compliance, manufacturing capability, labeling, distribution, and intellectual property outside the Orange Book.

An NDA-based miconazole product could have a different regulatory and patent profile, but the typical seven-day OTC vaginal products are not principally protected through listed NDA patents.

When does Miconazole 7 lose exclusivity?

Miconazole 7 has no meaningful remaining active-ingredient exclusivity period. The principal regulatory barrier is compliance with the OTC monograph, not expiration of a current molecule patent.

Exclusivity or barrier	Current commercial position
Basic miconazole patent	Expired or commercially irrelevant
FDA new-drug exclusivity	Not the normal basis for OTC monograph products
Orange Book patent exclusivity	Generally not applicable
Pediatric exclusivity	Not a meaningful current barrier
Formulation patents	May remain if product-specific
Trademark protection	May remain for brands such as Monistat
Trade dress and packaging	May remain, subject to scope
Manufacturing know-how	Can remain commercially important without patent protection

The main barrier to entry is execution: validated formulation, compliant labeling, quality systems, reliable filling, and retail distribution.

Which companies compete in the Miconazole 7 market?

The market includes branded OTC products, retailer private labels, contract manufacturers, and regional generic suppliers. Monistat is the best-known U.S. branded franchise associated with miconazole vaginal therapy. Private-label products compete through lower pricing and retailer placement.

The competitive set includes:

• Miconazole 7-day vaginal creams.
• Miconazole one-day and three-day regimens.
• Clotrimazole vaginal products.
• Tioconazole one-dose products.
• Prescription oral or vaginal fluconazole, subject to clinical appropriateness.
• Non-drug products marketed for vaginal comfort, which do not substitute for antifungal treatment.

A seven-day regimen may appeal to consumers seeking a lower per-dose concentration or a traditional treatment course. One-day and three-day products compete on convenience. The principal commercial tradeoff is treatment duration versus perceived speed and ease of use.

What licensing deals and manufacturing opportunities exist?

Miconazole 7 does not require a special license to the active ingredient for standard OTC manufacture. Commercial opportunities instead arise through:

• Private-label supply agreements with pharmacy chains.
• Contract manufacturing of cream or ovule dosage forms.
• Brand licensing for established OTC names.
• Co-development of applicators and packaging.
• Regional distribution rights.
• Acquisition of an existing OTC dossier, manufacturing site, or trademark portfolio.

Manufacturing barriers are more important than molecule access. A supplier needs controlled particle-size handling, validated homogeneity, preservative or microbial-control systems, filling accuracy, container-closure integrity, and stability data under retail distribution conditions.

For vaginal creams, the highest-value manufacturing capabilities are emulsion control, suspension uniformity, tube or applicator filling, and compatibility testing. For ovules, thermal processing, mold filling, cooling control, and resistance to deformation are central.

What generic launch risks exist for Miconazole 7?

A new entrant faces relatively low legal entry risk but meaningful commercial and quality risk.

Regulatory risks

• Incorrect active-ingredient concentration.
• Noncompliant indication or warning language.
• Inadequate preservative efficacy.
• Failure to demonstrate content uniformity.
• Unsupported superiority claims.
• Inadequate stability data.
• Packaging that fails under heat exposure.
• Latex-compatibility claims without sufficient testing.

Commercial risks

• Weak retailer placement.
• Low repeat purchase due to leakage or irritation.
• Consumer confusion between one-, three-, and seven-day products.
• Price competition from private labels.
• Higher-than-expected returns caused by melting or applicator defects.
• Limited differentiation from existing generic cream products.

Litigation risks

Patent litigation is less likely to arise from the miconazole active ingredient. Risk is more likely to involve:

• Trademark infringement.
• Trade dress.
• Applicator patents.
• Formulation patents.
• False or unsupported advertising claims.
• Contract disputes involving private-label supply.

No standard Paragraph IV litigation pathway should be assumed for an ordinary OTC monograph Miconazole 7 launch.

How strong is the patent estate for Miconazole 7?

The core patent estate is weak because the active ingredient is mature and widely available. A secondary formulation or device estate can be stronger if it has:

1. Narrowly defined but commercially unavoidable claim limitations.
2. Demonstrated stability or release advantages.
3. Claims covering the finished product rather than only an optional excipient.
4. Continuation or divisional support.
5. Claims that survive design-around analysis.
6. Evidence connecting the formulation to measurable clinical or usability benefits.

For a new entrant, freedom-to-operate analysis should focus on formulation-specific patents, applicator claims, packaging claims, and trademarks. A standard miconazole nitrate 2% cream using conventional excipients is more likely to face competition from market economics than from blocking patents.

Key Takeaways

• Miconazole 7 is typically a seven-day OTC vaginal regimen using 2% cream or 100 mg vaginal units.
• FDA OTC monograph compliance is more important than molecule exclusivity.
• The active ingredient is long off patent.
• Cream excipients commonly include mineral oil, petrolatum, stearyl alcohol, water, and benzoic acid, depending on the product.
• The strongest formulation opportunities involve lower irritation, reduced leakage, latex compatibility, and improved applicators.
• Orange Book and Paragraph IV strategies generally do not define entry for ordinary OTC monograph products.
• Patent risk is concentrated in secondary formulations, delivery devices, packaging, trademarks, and trade dress.
• Commercial value depends on private-label access, manufacturing quality, retailer distribution, and consumer usability.
• Biosimilar risk is not applicable because miconazole is a small-molecule antifungal, not a biologic.
• A differentiated non-oil, low-residue, latex-compatible seven-day product has the clearest formulation-led opportunity.

FAQs

Is Miconazole 7 a generic drug or an OTC monograph product?

It is commonly marketed as an OTC monograph product when the formulation and labeling comply with FDA requirements. Individual products may have different regulatory histories.

Can an oil-free Miconazole 7 formulation avoid condom warnings?

Potentially, but the finished product requires compatibility testing with relevant latex condoms and diaphragms. Oil removal alone does not establish compatibility.

Are vaginal mucoadhesive polymers patentable in a miconazole product?

They may be patentable when combined with novel composition, concentration, release, or performance limitations. Routine use of a known polymer may face novelty or obviousness challenges.

Does miconazole compete directly with fluconazole?

Yes, both are used for vulvovaginal candidiasis, but they differ in route, prescription status, contraindications, patient preference, and clinical suitability.

Is a seven-day miconazole product easier to launch than a one-day product?

Regulatory entry may be similar under the OTC monograph. Commercial entry can be easier for a seven-day product if the developer avoids complex high-dose release and irritation issues, but convenience-oriented one-day products often have stronger consumer appeal.

References

1. U.S. Food and Drug Administration. (2022). OTC Monograph M013: Antifungal drug products for over-the-counter human use. FDA.
2. Electronic Code of Federal Regulations. (2024). 21 C.F.R. Part 333, Subpart D: Antifungal drug products for over-the-counter human use.
3. Bayer HealthCare LLC. (2023). Monistat 7 vaginal cream: Drug facts and inactive ingredients. DailyMed.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.